IVMED-80
Keratoconus
Phase 2/3 (assumed post-ODD)Active (Licensed to Glaukos)
Key Facts
Indication
Keratoconus
Phase
Phase 2/3 (assumed post-ODD)
Status
Active (Licensed to Glaukos)
Company
About iVeena Delivery Systems
iVeena Delivery Systems is a clinical-stage biotech company pioneering pharmacologic treatments for refractive eye diseases, with a focus on keratoconus and pediatric myopia. The company has achieved key milestones, including an Orphan Drug Designation for IVMED-80 and an open IND for IVMED-85, supported by recent Series B-2 financing. Led by a team with deep expertise in ophthalmology and drug delivery, iVeena is advancing its first-in-class eyedrop formulations into clinical trials to address significant unmet needs in ocular health.
View full company profileTherapeutic Areas
Other Keratoconus Drugs
| Drug | Company | Phase |
|---|---|---|
| Intra-corneal Implant | MAG Optics | Pre-clinical |